Contribute Try STAT+ Today

Amid rising tension between drug makers and compound pharmacies, the Food and Drug Administration has issued new policies that seek to bolster manufacturing standards for compounded medicines and, in the process, may serve to establish competitive boundaries between these rival sets of companies.

A key piece of the effort focuses on a contentious issue: compounded drugs that, essentially, may be copies of prescription medicines. The agency specifies that compounders should not copy FDA-approved drugs, except when shortages exist.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Anyone concerned about patient health and the cost of prescription drugs should fight this, including payers, insurers, employers, physicians and patients. There are plenty of patients who cannot tolerate some of the additives in prescription drugs, or need different formulations or dosages. Once again, FDA reveals its true colors as an agency more protective of industry interests than patient health. It is captured nearly lock, stock and barrel by the ‘stakeholders’ that benefit from the status quo and tightening the screws to lock down their monopolies, patents and rights to sell dangerous devices that are now banned or withdrawn from sale in other nations given the extent of patient harm.

Comments are closed.